Understanding and targeting the challenges in treating small cell lung cancer
Official title: Investigating and Targeting Replication Stress in Small Cell Lung Cancer
Funded at New York University School of Medicine · NIH-10848843 · Data updated 2026-11-12
This study is looking at small cell lung cancer to understand why some types respond better to chemotherapy than others, focusing on a protein called SLFN11, with the hope of finding new ways to help patients whose cancer doesn’t respond to treatment.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 16, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $1,893,978 |
| NIH project number | 1P01CA288368-01 |
| Project ID | NIH-10848843 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with small cell lung cancer, particularly those who have experienced relapse after initial chemotherapy.
✕Less likely to help
Patients with non-small cell lung cancer or those who have not undergone chemotherapy may not benefit from this research.
What this research studies
This research focuses on small cell lung cancer (SCLC), a highly aggressive form of lung cancer that often relapses after initial treatment. The project aims to identify the molecular factors that influence how different SCLC subtypes respond to chemotherapy, particularly looking at the role of a specific protein called SLFN11. Additionally, the researchers will explore how various pathways related to replication stress affect the cancer's sensitivity to treatment. By integrating these findings, the goal is to develop new strategies to overcome treatment resistance in SCLC patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for small cell lung cancer, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting replication stress in other cancer types, suggesting that this approach may be effective for small cell lung cancer as well.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Huang, Tony Tung — New York University School of Medicine
- Study coordinator: Huang, Tony Tung
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.